In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Spero Therapeutics Inc (NASDAQ: SPRO), with a price target of $27. The company’s shares opened today at $9.33, close to its 52-week low of $7.88.
Chen said:
“We rate SPRO Overweight. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 9.9% and a 40.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Spero Therapeutics Inc is a Moderate Buy with an average price target of $23.25.
See today’s analyst top recommended stocks >>
Based on Spero Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.96 million. In comparison, last year the company had a GAAP net loss of $9.84 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.
